Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,030 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety.
Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W. Meltzer EO, et al. Among authors: price d. Allergy Asthma Proc. 2012 Jul-Aug;33(4):324-32. doi: 10.2500/aap.2012.33.3587. Allergy Asthma Proc. 2012. PMID: 22856633 Clinical Trial.
Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis.
Meltzer E, Ratner P, Bachert C, Carr W, Berger W, Canonica GW, Hadley J, Lieberman P, Hampel FC, Mullol J, Munzel U, Price D, Scadding G, Virchow JC, Wahn U, Murray R, Bousquet J. Meltzer E, et al. Among authors: price d. Int Arch Allergy Immunol. 2013;161(4):369-77. doi: 10.1159/000351404. Epub 2013 May 4. Int Arch Allergy Immunol. 2013. PMID: 23652808 Free article. Clinical Trial.
Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis.
Berger WE, Shah S, Lieberman P, Hadley J, Price D, Munzel U, Bhatia S. Berger WE, et al. Among authors: price d. J Allergy Clin Immunol Pract. 2014 Mar-Apr;2(2):179-85. doi: 10.1016/j.jaip.2013.09.019. Epub 2014 Jan 1. J Allergy Clin Immunol Pract. 2014. PMID: 24607046 Clinical Trial.
Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps.
Bousquet J, Bachert C, Bernstein J, Canonica GW, Carr W, Dahl R, Demoly P, Devillier P, Hellings P, Fokkens W, Klimek L, Lieberman P, Meltzer E, Price D, Ryan D, Wahn U. Bousquet J, et al. Among authors: price d. Expert Opin Pharmacother. 2015 Apr;16(6):913-28. doi: 10.1517/14656566.2015.1020789. Epub 2015 Mar 7. Expert Opin Pharmacother. 2015. PMID: 25747125 Review.
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision.
Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, Brignardello-Petersen R, Canonica GW, Casale T, Chavannes NH, Correia de Sousa J, Cruz AA, Cuello-Garcia CA, Demoly P, Dykewicz M, Etxeandia-Ikobaltzeta I, Florez ID, Fokkens W, Fonseca J, Hellings PW, Klimek L, Kowalski S, Kuna P, Laisaar KT, Larenas-Linnemann DE, Lødrup Carlsen KC, Manning PJ, Meltzer E, Mullol J, Muraro A, O'Hehir R, Ohta K, Panzner P, Papadopoulos N, Park HS, Passalacqua G, Pawankar R, Price D, Riva JJ, Roldán Y, Ryan D, Sadeghirad B, Samolinski B, Schmid-Grendelmeier P, Sheikh A, Togias A, Valero A, Valiulis A, Valovirta E, Ventresca M, Wallace D, Waserman S, Wickman M, Wiercioch W, Yepes-Nuñez JJ, Zhang L, Zhang Y, Zidarn M, Zuberbier T, Schünemann HJ. Brożek JL, et al. Among authors: price d. J Allergy Clin Immunol. 2017 Oct;140(4):950-958. doi: 10.1016/j.jaci.2017.03.050. Epub 2017 Jun 8. J Allergy Clin Immunol. 2017. PMID: 28602936 Free article.
5,030 results